McAdam LLC lessened its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 5.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,650 shares of the exchange traded fund’s stock after selling 413 shares during the period. McAdam LLC’s holdings in SPDR S&P Biotech ETF were worth $756,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also added to or reduced their stakes in XBI. Affinity Asset Advisors LLC increased its position in SPDR S&P Biotech ETF by 105.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 37,550 shares of the exchange traded fund’s stock worth $3,481,000 after buying an additional 737,550 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its position in SPDR S&P Biotech ETF by 30.3% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,136,000 shares of the exchange traded fund’s stock worth $297,575,000 after buying an additional 730,000 shares during the period. Mirae Asset Securities USA Inc. bought a new position in SPDR S&P Biotech ETF during the 2nd quarter worth $55,626,000. Jane Street Group LLC increased its position in SPDR S&P Biotech ETF by 68.7% during the 1st quarter. Jane Street Group LLC now owns 961,082 shares of the exchange traded fund’s stock worth $91,197,000 after buying an additional 391,333 shares during the period. Finally, Baymount Management LP bought a new position in SPDR S&P Biotech ETF during the 1st quarter worth $34,160,000.
SPDR S&P Biotech ETF Stock Performance
XBI opened at $97.25 on Friday. The firm has a market cap of $7.41 billion, a P/E ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 52-week low of $63.80 and a 52-week high of $103.52. The business’s fifty day moving average is $99.16 and its 200-day moving average is $94.55.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- High Flyers: 3 Natural Gas Stocks for March 2022
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Profitably Trade Stocks at 52-Week Highs
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.